## UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_\_

BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

SAWAI USA, INC. AND SAWAI PHARMACEUTICAL CO., LTD., Petitioners,

v.

BIOGEN MA INC., Patent Owner.

\_\_\_\_\_

IPR2019-00789 U.S. Patent No. 8,399,514

**BIOGEN EXHIBIT LIST** 



Further to 37 C.F.R. § 42.63(e), Patent Owner hereby submits a current listing of its exhibits. Exhibits 2006-2008, 2010-2012, 2014-2017 are being filed today.

EXHIBIT	DESCRIPTION
Exhibit 2001	Press Release, Upsher-Smith's Parent Company Forms Strategic Alliance with Sumitomo Corporation in US Generics Market (Nov. 13, 2017) (available at https://www.upshersmith.com/wpcontent/uploads/CO-PR-Sumitomo-Strategic-Alliance-USLFINAL.pdf)
Exhibit 2002	Press Release, Sumitomo Corporation Participates in Generic Pharmaceutical Business in the U.S. (Nov. 13, 2017) (available at https://www.sumitomocorp.com/en/jp/news/release/2017/group/20171113_2)
Exhibit 2003	Summons in a Civil Action on Defendant Sawai USA Inc., Biogen Int'l GmbH & Biogen MA Inc. v. Sawai USA, Inc. & Sawai Pharmaceutical Co. Ltd., No. 1:17-cv-00875-LPS, Dkt. 5 (D. Del. July 5, 2017)
Exhibit 2004	Scheduling Order, <i>Biogen Int'l GmbH &amp; Biogen MA Inc. v. Amneal Pharmaceuticals, et al.</i> , No. 1:17-00823-LPS, Dkt. 22 (D. Del. February 2, 2018)
Exhibit 2005	Transcript of May 14, 2019 teleconference with APJs Sheridan K. Snedden, Jennifer M. Chagnon, and Jacqueline T. Harlow, counsel for Patent Owner Biogen MA Inc. and counsel for Petitioner Sawai USA, Inc. and Sawai Pharmaceutical Co. Ltd.
Exhibit 2006	Email from Andrew Kellogg, Supervisory Paralegal, Patent Trial and Appeal Board, USPTO (June 3, 2019)
Exhibit 2007	ANDA 210285 Tentative Approval Letter (available at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/21 0285Orig1s000TA ltr.pdf)
Exhibit 2008	CenterWatch News Online, Sawai Pharmaceutical to acquire Upsher-Smith Laboratories U.S. generics business (Apr. 20, 2017) (available at https://www.centerwatch.com/news-online/2017/04/20/sawai-pharmaceutical-acquire-upsher-smith-laboratories-u-s-generics-business/)



EXHIBIT	DESCRIPTION
Exhibit 2009	RESERVED
Exhibit 2010	Sawai Pharmaceutical Co., Ltd. Integrated Report 2018 (available at https://ssl4.eir-parts.net/doc/4555/ir material for fiscal ym15/53096/00.pdf)
Exhibit 2011	Sumitomo Corporation Integrated Report 2018 (available at https://www.sumitomocorp.com/-/media/Files/hq/ir/report/investors-guide/2018/integrated-2018en.pdf?la=en)
Exhibit 2012	FY2018 Business Unit IR Meeting (May 28, 2018) (available at https://www.sumitomocorp.com/-/media/Files/hq/ir/explain/business/en/20180528IRQA_SHIGEN_ENG.pdf?la=en)
Exhibit 2013	RESERVED
Exhibit 2014	Press Release, Upsher-Smith's Parent Company Completes Stake Transfer To Sumitomo Corporation In US Generics Market (Jan. 5, 2018) (available at https://www.prnewswire.com/news-releases/upsher-smiths-parent-company-completes-stake-transfer-to-sumitomo-corporation-in-us-generics-market-300578294.html)
Exhibit 2015	Sumitomo Corporation, Integrated Solution Provider for Pharmaceutical Industry "From upstream to downstream" (available at https://www.sumitomocorp.com/en/us/business/case/group/236)
Exhibit 2016	Complaint in a Civil Action, Biogen Int'l GmbH & Biogen MA Inc. v. Sawai USA, Inc. & Sawai Pharmaceutical Co. Ltd., No. 1:17-cv-00875-LPS, Dkt. 1 (D. Del. June 30, 2017)
Exhibit 2017	Trial Transcript in a Civil Action, <i>Procter &amp; Gamble Pharm., Inc. et al. v. Hoffmann-LaRoche, Inc. et al.</i> , No. 06-civ-34 (S.D.N.Y. May 25, 2006)



## Respectfully submitted,

Dated: June 14, 2019 By: / Barbara C. McCurdy /

Barbara C. McCurdy, Reg. No. 32,120 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 (202) 408-4047 Counsel for Patent Owner



## **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing **Biogen Exhibit List** and **Exhibits 2006-2008, 2010-2012, 2014-2017** were served electronically via the PTAB electronic filing system and via email on June 14, 2019, in their entirety on the following:

Brian Sodikoff Katten Muchin Rosenman LLP 525 West Monroe Street Chicago, IL 60661-3693 Telephone: (312) 902-5462

E-mail: brian.sodikoff@kattenlaw.com

Christopher B. Ferenc Katten Muchin Rosenman LLP 2900 K Street NW North Tower - Suite 200 Washington, DC 20007 Telephone: (202) 625-3647

E-mail: Christopher.ferenc@kattenlaw.com

Petitioner has agreed to electronic service.

Dated: June 14, 2019 By: / Catherine A. Sadler /

Catherine A. Sadler Case Manager

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP

